

- (51) International Patent Classification:

C07D 213/61 (2006.01) C07D 413/14 (2006.01)
- (21) International Application Number:

PCT/EP2024/063879
- (22) International Filing Date:

21 May 2024 (21.05.2024)
- (25) Filing Language:

English
- (26) Publication Language:

English
- (30) Priority Data:

23174500.1 22 May 2023 (22.05.2023) EP
- (71) Applicant: CHIESI FARMACEUTICI S.p.A. [IT/IT];

Via Palermo 26/A, 43122 Parma (IT).
- (72) Inventors: BOCCHI, Monica; c/o Chiesi Farmaceutici S.p.A., Via Palermo 26/A, 43122 Parma (IT). CARDI-NALI, Luca; c/o Chiesi Farmaceutici S.p.A., Via Palermo 26/A, 43122 Parma (IT). PIVETTI, Fausto; c/o Chiesi Farmaceutici S.p.A., Via Palermo 26/A, 43122 Parma (IT). MARI, Massimiliano; c/o Chiesi Farmaceutici S.p.A., Via Palermo 26/A, 43122 Parma (IT). RONCHI, Paolo; c/o Chiesi Farmaceutici S.p.A., Via Palermo 26/A, 43122 Parma (IT). LATHBURY, David C.; c/o Chiesi Farmaceutici S.p.A., Via Palermo 26/A, 43122 Parma (IT). MARIANI, Edoardo; c/o Chiesi Farmaceutici S.p.A., Via Palermo 26/A, 43122 Parma (IT).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: PROCESS AND INTERMEDIATES FOR THE PREPARATION OF A P2X₃ INHIBITOR

(57) Abstract: The present invention relates to a process for the preparation of a P2X₃ inhibitor, i.e. (R)-6- (5-fluoropyridin-2-yl)-8-methoxy-N-(1-(5-methyl-1,2,4-oxadiazol-3-yl)ethyl)quinazolin-4- amine, or a pharmaceutically acceptable salt thereof. It also relates to intermediate compounds which are useful in such process and their preparation thereof. The synthesized P2X₃ inhibitor is suitable for medical use in pharmaceutical applications.